Phenotypes of idiopathic pulmonary arterial hypertension

医学 心脏病学 内科学 肺动脉高压 表型 重症监护医学 遗传学 生物 基因
作者
Roberto Badagliacca,Raymond L. Benza,Giovanna Manzi,Khodr Tello,Robert Naeije
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:10 (10): e89-e89
标识
DOI:10.1016/s2213-2600(22)00308-3
摘要

We read with great interest the registry analysis by Marius M Hoeper and colleagues1Hoeper MM Dwivedi K Pausch C et al.Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022; 10: 937-948Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar suggesting that patients with idiopathic pulmonary arterial hypertension (IPAH) and a lung phenotype defined by a lung diffusion capacity for carbon monoxide (DLCO) of less than 45% of the predicted value and a smoking history have a worse prognosis than do patients with more classical IPAH.1Hoeper MM Dwivedi K Pausch C et al.Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022; 10: 937-948Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar But what is the exact meaning of classical IPAH now? The historical National Institute of Health (NIH) registry of “primary pulmonary hypertension” established a classical IPAH phenotype of predominantly female, young to middle-aged adults with no cardiac or respiratory diseases. In that registry, close to half of the patients were smokers and approximately one-third of the patients had a very low DLCO.2Rich S Dantzker DR Ayres SM et al.Primary pulmonary hypertension. A national prospective study.Ann Intern Med. 1987; 107: 216-223Crossref PubMed Scopus (1732) Google Scholar As a crude estimate, some 15–30% of the patients would have presented with a lung phenotype. In the case-control study that identified appetite suppressants as a cause of IPAH, a smoking history was found to be unrelated to the disease.3Abenhaim L Moride Y Brenot F et al.Appetite-suppressant drugs and the risk of primary pulmonary hypertension.N Engl J Med. 1996; 335: 609-616Crossref PubMed Scopus (1075) Google Scholar As mentioned by Hoeper and colleagues, the smoking rodent is an experimental model of emphysema, not PAH.1Hoeper MM Dwivedi K Pausch C et al.Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022; 10: 937-948Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar The lung phenotype of IPAH might be three times more common in some registries than in others.1Hoeper MM Dwivedi K Pausch C et al.Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022; 10: 937-948Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar Thus, further studies might be needed to better define the lung phenotype of IPAH and its pathophysiology. In the meantime, we might prefer to understand classical IPAH as defined in the NIH registry. Another intriguing aspect of the report by Hoeper and colleagues1Hoeper MM Dwivedi K Pausch C et al.Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022; 10: 937-948Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar is that more than half of their patients with classical IPAH achieved a low-risk status at follow-up, whereas most (67%) of them were on only one targeted therapy. In the Italian Pulmonary Hypertension network, this good result was achieved in only 31% of the patients with IPAH, with 70% of them on monotherapies. Other registries show even less favourable results.4Weatherald J Boucly A Chemla D et al.Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension.Circulation. 2018; 137: 693-704Crossref PubMed Scopus (109) Google Scholar Whether these differences can be explained only by exclusion or inclusion of patients with very low DLCO deserves scrutiny. However, over-optimistic results of monotherapies in classical IPAH or very poor prognosis in the lung phenotype IPAH should not distract clinicians from treating these patients with initial combinations of drugs following updated risk assessment-guided treatment algorithms.5Badagliacca R D'Alto M Ghio S et al.Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension.Am J Respir Crit Care Med. 2021; 203: 484-492Crossref PubMed Scopus (27) Google Scholar The current tendency is to optimise titration of therapies based not only on risk scores, but also with determination of pulmonary vascular resistance and imaging of the right heart. Hoeper and colleagues are to be commended for their painstaking efforts to identify PAH subphenotypes in large registries. Their notion of a lung phenotype of IPAH deserves attention but requires validation in prospective explorations. As always with excellent studies, this one begs for more. RB reports personal fees from UT, Dompè, Ferrer, Bayer, MSD, AOP, and Orphan Pharmaceuticals, outside of the submitted work. RLB reports grants from Actelion, Bayer, Bellerophon, Eiger, and Abbott. GM declares no competing interests. KT has received speaking fees from Actelion and Bayer, outside of the submitted work. RN reports relationships including consultancies, speaker's fees, and membership of advisory boards with AOP, Orphan Pharmaceuticals, Johnson & Johnson, Lung Biotechnology Corporation, and United Therapeutics. All authors contributed to writing of this Correspondence and approved the manuscript for submission. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysisA cohort of patients meeting diagnostic criteria for IPAH with a distinct, presumably smoking-related form of pulmonary hypertension accompanied by a low DLCO, resemble patients with pulmonary hypertension due to lung disease rather than classical IPAH. These observations have pathogenetic, diagnostic, and therapeutic implications, which require further exploration. Full-Text PDF Open AccessPhenotypes of idiopathic pulmonary arterial hypertensionWe applaud the recent article in The Lancet Respiratory Medicine by Marius M Hoeper and colleagues,1 which highlights a unique group of patients with pulmonary hypertension who meet the diagnostic criteria for group 1 pulmonary arterial hypertension (PAH) but have a lung phenotype characterised by older age, substantial smoking history, male predominance, substantial reduction of diffusion capacity for carbon monoxide, and a clinical course that is similar to group 3 pulmonary hypertension rather than group 1. Full-Text PDF Phenotypes of idiopathic pulmonary arterial hypertensionIn recent work, Marius M Hoeper and colleagues1 showed a remarkably high mortality among patients classified as having idiopathic pulmonary arterial hypertension with a lung phenotype (IPAH-LP). In their elegant paper combining data from the COMPERA and ASPIRE registries, this phenotype was composed of predominantly male patients with a smoking habit, and a median diffusing capacity for carbon monoxide (DLCO) of 30% (COMPERA) and 27% (ASPIRE). Full-Text PDF Phenotypes of idiopathic pulmonary arterial hypertension – Authors' replyAlejandro Cruz-Utrilla and colleagues suggest that the cohort we described as having idiopathic pulmonary arterial hypertension (IPAH) with a lung phenotype1 might have pulmonary veno-occlusive disease (PVOD). However, IPAH with a lung phenotype is distinct from PVOD: chest CT studies from ASPIRE were reviewed by radiologists with expertise in pulmonary disease, and radiological features of PVOD were not identified in our study; patients with PVOD might develop pulmonary oedema following pulmonary arterial hypertension therapy (however, this has not been observed in our cohort); histological data from 24 patients with IPAH with a lung phenotype show vascular pruning with capillary rarefication, whereas only 13% had features mimicking PVOD;2 PVOD remains uncommon, whereas our carefully phenotyped cohort might be more prevalent than classical IPAH;3 and pulmonary venous involvement can be found in a third of IPAH lung specimens,4 so histological demonstration of pulmonary venous involvement is insufficient to diagnose PVOD, a condition characterised by widespread venous obliteration, dilated capillaries, and angioproliferative lesions. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
snow完成签到 ,获得积分10
1秒前
zzz完成签到,获得积分10
1秒前
所所的应助被dongdong采纳,获得10
2秒前
慕青的应助被Anthony采纳,获得10
2秒前
bonnie12完成签到,获得积分10
3秒前
5秒前
zc完成签到,获得积分10
9秒前
爱做梦的火烈鸟完成签到,获得积分10
10秒前
10秒前
小琪发布了新的文献求助10
11秒前
iedq完成签到 ,获得积分0
12秒前
阳光蚂蚁完成签到,获得积分10
12秒前
13秒前
FashionBoy的应助被mu采纳,获得10
14秒前
我是老大的应助被懦弱的冷珍采纳,获得10
14秒前
14秒前
红枣泡枸杞完成签到,获得积分10
15秒前
18秒前
turbohero发布了新的文献求助30
18秒前
21秒前
JJW完成签到,获得积分10
21秒前
白桃战士完成签到,获得积分10
24秒前
24秒前
难过立辉完成签到 ,获得积分10
24秒前
27秒前
天真的向南完成签到 ,获得积分10
28秒前
28秒前
Maestro_S的应助被旅行者8号采纳,获得10
31秒前
YYJ完成签到,获得积分10
31秒前
32秒前
小屎壳郎发布了新的文献求助30
33秒前
浪客剑心完成签到,获得积分10
33秒前
Channingh发布了新的文献求助10
33秒前
CYJ的应助被初度采纳,获得10
34秒前
34秒前
猫猫完成签到 ,获得积分10
35秒前
wiliiam完成签到,获得积分10
36秒前
张维为发布了新的文献求助10
37秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191072
求助须知:如何正确求助?哪些是违规求助? 9578083
关于积分的说明 21856545
捐赠科研通 7790236
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483237